Page 1

August 5 , 2021 XOMA XOMA Reports Second Quarter 2021 Financial Results and Highlights Recent Operational Events Added six assets to its portfolio of potential milestone and royalty assets in 2021 Company earned $ 0.5 million milestone as Janssen asset entered Phase 3 development NIS793 in combination with standard of care chemotherapy was granted Orphan Drug Designation for the treatment pancreatic cancer DAY101 received Rare Pediatric Disease Designation for the treatment of pediatric low- grade glioma XOMA raised $ 40 million through its Series B Perpetual Preferred Stock offering paying 8.375 % dividend Board of Directors declared quarterly dividend payments for XOMAP and XOMAO Company paid off all outstanding debt and ended the second quarter of 2021 with $ 78.9 million in cash EMERYVILLE , Calif . , Aug. 05 , 2021 ( GLOBE NEWSWIRE ) -- XOMA Corporation ( Nasdaq : XOMA ) reported its second quarter 2021 financial results and provided a recent operations update . " The events we have announced over the past four months reflect many more months of hard work by our team and our partners . On the acquisition side of our potential milestone and royalty asset business , we added Day One Biopharmaceuticals ' DAY101 ( pan - RAF kinase inhibitor ) , Checkmate Pharmaceuticals ' vidotulimod ( CMP - 001 ) , and Denovo Biopharma's vosaroxin ( topoisomerase II inhibitor ) to our growing list of partner - funded assets . XOMA's legacy technology license agreements resulted in the addition of three clinical - stage assets being developed by Affimed to our portfolio , " stated Jim Neal , Chief Executive Officer of XOMA . " Our asset partners also have had successes with assets in XOMA's portfolio . In May , Janssen launched a Phase 3 study with cetrelimab ( anti - PD - 1 monoclonal antibody ) . In conjunction with the first NIS793 ( anti - TGFß monoclonal antibody ) clinical data presentation at ASCO in June , Novartis announced its intention to begin a Phase 3 study with NIS793 later in 2021. Also at ASCO , AVEO reported data from the ficlatuzumab Phase 2 study in head and neck squamous cell carcinoma and its desire to move ficlatuzumab into Phase 3 development . Last week , we were pleased to learn of two important designations granted by